1.285
Zentalis Pharmaceuticals Inc stock is traded at $1.285, with a volume of 643.25K.
It is down -5.17% in the last 24 hours and down -33.07% over the past month.
See More
Previous Close:
$1.355
Open:
$1.26
24h Volume:
643.25K
Relative Volume:
0.38
Market Cap:
$92.28M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.283
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
-28.21%
1M Performance:
-33.07%
6M Performance:
-59.84%
1Y Performance:
-91.77%
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ZNTL
Zentalis Pharmaceuticals Inc
|
1.285 | 92.28M | 0 | -292.19M | -208.41M | -4.54 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
Jun-20-24 | Downgrade | UBS | Buy → Neutral |
Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
Jul-12-22 | Initiated | Cowen | Outperform |
Apr-06-22 | Initiated | Wells Fargo | Overweight |
Oct-07-21 | Resumed | Jefferies | Buy |
Sep-30-21 | Initiated | Stifel | Buy |
Sep-29-21 | Initiated | Oppenheimer | Outperform |
May-21-21 | Initiated | UBS | Buy |
Jan-20-21 | Initiated | Wedbush | Outperform |
Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
Aug-27-20 | Initiated | H.C. Wainwright | Buy |
Apr-28-20 | Initiated | Guggenheim | Buy |
Apr-28-20 | Initiated | Jefferies | Buy |
Apr-28-20 | Initiated | Morgan Stanley | Overweight |
Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages - Defense World
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zentalis Strengthens Team with $194,600 in Equity Incentives - Stock Titan
Virtu Financial LLC Buys Shares of 24,973 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Leerink Partnrs Issues Pessimistic Outlook for ZNTL Earnings - Defense World
What is HC Wainwright’s Forecast for ZNTL Q1 Earnings? - Defense World
Leerink Partnrs Has Pessimistic Outlook of ZNTL Q1 Earnings - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Position Lifted by Charles Schwab Investment Management Inc. - Defense World
Wedbush Reiterates Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals: Hold Rating Amid Clinical Progress and Financial Uncertainty - TipRanks
Bank of New York Mellon Corp Sells 10,375 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives “Buy” Rating from HC Wainwright - Defense World
Zentalis Pharmaceuticals Reports Progress and Financials - TipRanks
Stifel maintains Buy on Zentalis stock with $9 target By Investing.com - Investing.com Canada
H.C. Wainwright sets $10 target for Zentalis shares, maintains Buy By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals Inc Reports Annual EPS of -$2.33, Excee - GuruFocus
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates - GlobeNewswire
Zentalis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zentalis Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - Marketscreener.com
Zentalis Breakthrough: 35% Response Rate in Ovarian Cancer Trial Wins FDA Fast Track - Stock Titan
Zentalis Pharmaceuticals to Present Multiple Posters at the - GlobeNewswire
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 - TradingView
Zentalis Pharmaceuticals Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
Zentalis pharmaceuticals director Luke Walker buys $24,966 in stock - MSN
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Buy Rating from HC Wainwright - The AM Reporter
H.C. Wainwright maintains $10 target on Zentalis stock By Investing.com - Investing.com Canada
Zentalis Highlights Promising Azenosertib Data at SGO 2025 - TipRanks
Zentalis Pharmaceuticals Presents Updated Clinical Data at - GlobeNewswire
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - MarketScreener
Zentalis Announces Updated Clinical Data From Part 1b Of DENALI Trial Of Azenosertib In PROC - Nasdaq
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - TradingView
Breakthrough: Zentalis Drug Achieves 35% Response Rate Against Hard-to-Treat Ovarian Cancer - Stock Titan
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Has Been Trading Down. What Are The Prospects For The Future? - stocksregister.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Brokerages - Defense World
ZNTL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire
How Zentalis Is Attracting Talent: Inside Their Latest Employee Compensation Package - StockTitan
Zentalis Pharmaceuticals Announces Multiple Data - GlobeNewswire
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - The Manila Times
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - Yahoo Finance
A company insider recently bought 20,000 shares of Zentalis Pharmaceuticals Inc [ZNTL]. Should You Buy? - Knox Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc.ZNTL - PR Newswire
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Can Zentalis' Novel Cancer Drug Pipeline Impress at Two Elite Healthcare Conferences? - StockTitan
Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Tuesday - The AM Reporter
Zentalis stock price target cut to $10 by H.C. Wainwright - MSN
Zentalis pharmaceuticals officer sells $24,590 in stock - MSN
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently - Yahoo Finance
Savant Capital LLC Acquires New Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis stock plunges to 52-week low, hits $2.16 - MSN
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):